Patents Issued in November 9, 2017
-
Publication number: 20170320877Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.Type: ApplicationFiled: July 18, 2017Publication date: November 9, 2017Inventors: Liangxing Wu, Liang Lu, Ding-Quan Qian, Bo Shen, Wenqing Yao
-
Publication number: 20170320878Abstract: The invention discloses a method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous Pd catalyzed fluoro, chloro and fluorochloro alkylation with fluoro, chloro and fluorochloroalkyl halides in the presence of di(1-adamantyl)-n-butylphosphine and in the presence of 2,2,6,6-tetramethylpiperidine 1-oxyl.Type: ApplicationFiled: November 5, 2015Publication date: November 9, 2017Applicant: Lonza LtdInventors: Christoph Taeschler, Florencio Zaragoza Doerwald, Stefan Ellinger, Matthias Beller, Helfried Neumann, Lin He, Kishore Natte
-
Publication number: 20170320879Abstract: The present invention provides processes for the preparation of ibrutinib, intermediate compounds of Formula VI and Formula VIII, and salts thereof. The processes of the present invention are commercially viable, cost-effective, environmentally friendly, and make use of inexpensive, non-hazardous, safe chemicals that are easy to handle.Type: ApplicationFiled: November 18, 2015Publication date: November 9, 2017Inventors: Kapil SHARMA, Bhavin Prabhudas THANKI, Mahavir Singh KHANNA, Mohan PRASAD
-
Publication number: 20170320880Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.Type: ApplicationFiled: May 5, 2017Publication date: November 9, 2017Inventors: Michael R. Michaelides, Michael L. Curtin, Huan-Qiu Li, Marina A. Pliushchev, Ying Wang, Hongyu H. Zhao, Richard F. Clark, Alan S. Florjancic, Zhiqin Ji, Mariazel Torrent, Ramzi F. Sweis, Anil Vasudevan, Justin D. Dietrich
-
Publication number: 20170320881Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.Type: ApplicationFiled: May 18, 2017Publication date: November 9, 2017Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
-
Publication number: 20170320882Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).Type: ApplicationFiled: July 21, 2017Publication date: November 9, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson
-
Publication number: 20170320883Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.Type: ApplicationFiled: July 13, 2017Publication date: November 9, 2017Inventors: Richard CHESWORTH, Oscar Miguel MORADEI, Gideon SHAPIRO, Lei JIN, Robert E. BABINE
-
Publication number: 20170320884Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: November 30, 2015Publication date: November 9, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Publication number: 20170320885Abstract: The present invention generally relates to a process for preparation of 9-halo-3-(2-haloacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one of Formula I, which is an intermediate in the preparation of Hepatitis C Virus (HCV) inhibitors.Type: ApplicationFiled: May 1, 2017Publication date: November 9, 2017Inventors: Krishna R. Yalamareddy, Clifton Leigh, Sankar Subramanian, Stephen Mccarron, Omar Depaolis, Lyndon Marble
-
Publication number: 20170320886Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: ApplicationFiled: July 24, 2017Publication date: November 9, 2017Applicant: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si Allston
-
Publication number: 20170320887Abstract: Disclosed is a novel urethane acrylate being a reaction product of a raw material composition comprising at least (A) a diol component, (B) a component having acrylic unsaturation and (C) an isocyanate component. Said component (A) comprises at least one alkoxylated 2,4,8,10-tetraoxaspiro[5.5]undecane-3,9-dialkanol, component (B) comprises at least one hydroxyalkyl acrylate, hydroxyalkyl methacrylate and/or hydroxyalkyl methylacrylate, and/or comprises acrylic acid, methacrylic acid and/or a methylacrylic acid and/or a corresponding alkyl ester of a said acrylic acid, and said component (C) comprises at least one di or polyisocyanate or a derivative thereof.Type: ApplicationFiled: March 11, 2014Publication date: November 9, 2017Inventors: David James, Linda ZELLNER
-
Publication number: 20170320888Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: February 28, 2017Publication date: November 9, 2017Inventors: Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
-
Publication number: 20170320889Abstract: A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.Type: ApplicationFiled: November 30, 2015Publication date: November 9, 2017Applicant: C&C RESEARCH LABORATORIESInventors: Chan Hee PARK, Sang Hwi LEE, Junhwan IM, Soon Ok LEE, Jongmin KIM, Kwang Seok KO, Byungho KIM, Minjung KONG, Mi Sun KIM, Hyung Jo MOON
-
Publication number: 20170320890Abstract: The present invention relates to a novel 4-(aryl)-N-(2-alkoxythieno[3,2-b]pyrazin-3 -y)-piperazin-1-carboxamide derivative compound useful in the prevention or treatment of cancer; a preparation method thereof; and a pharmaceutical composition comprising the same. The novel 4-(aryl)-N(2-alkoxythieno[3,2-b]pyrazin-3-yl)-piperazin-1-carboxamide derivative compound of the present invention can effectively inhibit the growth of proliferating cells, and thus can be useful in the prevention or treatment of cancer.Type: ApplicationFiled: December 3, 2015Publication date: November 9, 2017Inventors: Young Dae Gong, Se Hun Kwak, Eun Sil Lee
-
Publication number: 20170320891Abstract: The present invention relates to novel series of substituted 7-(morpholinyl)-2-(N-piperazinyl)-methyl thieno [2, 3-c] pyridines of the following structure of formula I. Where in R1, R2, R3 and R4 are defined.Type: ApplicationFiled: December 11, 2014Publication date: November 9, 2017Inventors: Durga Prasad KONAKANCHI, Subba Rao PULA, Rama Krishna PILLI, Lakshmana Viswa Venkata Pavan Kumar MADDULA, Srinivasa Krishna Murthy KONDURI, Janaki Rama Rao RAVI, Naga Vasanta Srinivasu VUPPALAPATI, Sandeep Kumar THOOTA, Pulla Reddy MUDDASANI, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI
-
Publication number: 20170320892Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and/or reducing the risk of microbial infections in humans and animals.Type: ApplicationFiled: January 5, 2017Publication date: November 9, 2017Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Shili Chen, Marco Devivo, Rongliang Lou, Brian T. Wimberly
-
Publication number: 20170320893Abstract: Described herein is a process for the total synthesis of macrolactones and macrolactams of formula I including E- and Z-configuration thereof, in particular, nannocystins.Type: ApplicationFiled: May 9, 2017Publication date: November 9, 2017Inventors: Zhang WANG, Jun HUANG
-
Publication number: 20170320894Abstract: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C3-9alkyl-, —C1-5alkyl-NR13—C1-5alkyl-, —C1-5alkyl-NR14—CO—C1-5alkyl-, —C1-2alkyl-NR21—H2—CO—NH—C1-3alkyl- or —C1-2alkyl-NR23—CO—CR16R17—NH—; X1 represents O or —O—C1-2alkyl-; X2 represents a direct bond, C1-2alkyl, —CO—C1-2alkyl or NR12—C1-2alkyl; R1 represents hydrogen or halo; R2 represents halo, acetylene or Het1 R3 represents hydrogen or cyano; R4 represents Ar4—C1-4alkyloxy-, C1-4alkyloxy- or C1-4alkyloxy substituted with one or where possible two or more substituents selected from Het2, NR7R8, hydroxy and C1-4alkyloxy-C1-4alkyloxy-; R7 represents hydrogen or C1-4alkyl; R8 represents C1-4alkyl substituted with NR25R26 or C1-4alkylsulfonyl; R12 represents hydrogen or C1-4alkyl-; R13 represents Ar6-sulfonyl or C1-6alkyloxycarbonyl optionally substituted with phenyl; R16 and R17 represents hydrType: ApplicationFiled: May 22, 2017Publication date: November 9, 2017Inventors: Eddy Jean Edgard FREYNE, Marc WILLEMS, Peter TEN HOLTE, Alexandra PAPANIKOS, Werner Constant Johan EMBRECHTS, Pierre Henri STORCK, Virginie Sophie PONCELET
-
Publication number: 20170320895Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: May 19, 2017Publication date: November 9, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
-
Publication number: 20170320896Abstract: Isocyanate-functional silanes are prepared in high yield by pyrolysis of an O-carbamate prepared by reaction of a dialkylcarbonate with an aminoalkyl-functional silane in the presence of a basic catalyst, where the catalyst is neutralized by an acid which has a pKa of all protolysis stages of not more than 4. The neutralized or partially neutralized catalyst need not be removed prior to pyrolysis. The isocyanato-functional silanes exhibit higher storage stability as compared to those prepared from O-carbamates where catalyst neutralization is effected by weak acids.Type: ApplicationFiled: October 29, 2015Publication date: November 9, 2017Applicant: Wacker Chemie AGInventors: Volker STANJEK, Lars ZANDER
-
Publication number: 20170320897Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.Type: ApplicationFiled: July 21, 2017Publication date: November 9, 2017Inventors: Richard L. Beard, John E. Donello, Veena Wiswanath
-
Publication number: 20170320898Abstract: Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.Type: ApplicationFiled: May 30, 2017Publication date: November 9, 2017Inventors: Neil Hukriede, Billy W. Day, Lee A. McDermott
-
Publication number: 20170320899Abstract: Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.Type: ApplicationFiled: July 19, 2017Publication date: November 9, 2017Applicant: Plexxikon Inc.Inventors: Jiazhong Zhang, John Buell, Katrina Chan, Prabha N. Ibrahim, Jack Lin, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jeffrey Wu
-
Publication number: 20170320900Abstract: A process for enabling the production of a particulate composition containing crystalline trehalose dihydrate is provided. Including allowing an ?-glycosyltrehalose-forming enzyme to act on liquefied starch derived from a microorganism of the genus Arthrobacter and a trehalose-releasing enzyme derived from a microorganism of the genus Arthrobacter along with a starch debranching enzyme and a cyclomaltodextrin glucanotransferase; allowing glucoamylase to act on the resulting mixture to obtain a saccharide solution containing ?,?-trehalose; precipitating crystalline ?,?-trehalose dihydrate from the above saccharide solution; collecting the precipitated crystalline ?,?-trehalose dihydrate by a centrifuge; and ageing and drying the collected crystals. Cyclomaltodextrin glucanotransferase derived from a microorganism of the genus Paenibacillus or a mutant enzyme thereof is used to increase the ?,?-trehalose content in the saccharide solution to over 86.Type: ApplicationFiled: July 18, 2017Publication date: November 9, 2017Inventors: Takashi SHIBUYA, Seisuke IZAWA
-
Publication number: 20170320901Abstract: The present invention provides a new chemical process, a new cassette configuration, and new software for the automated production of multiple batches of an [18F]labelled compound on a single cassette. The invention allows one synthesizer in one hot cell to produce sequentially a plurality of batches of [18F]-labelled PET tracer in the same day. In particular, the present invention provides a novel arrangement useful for the trapping of [18F]fluoride and recovery of [18O]water.Type: ApplicationFiled: November 12, 2015Publication date: November 9, 2017Applicant: GE Healthcare LimitedInventors: Xavier Franci, Steve Lignon, Audrey Marie Lange, Nicolas Verbrugge
-
Publication number: 20170320902Abstract: Compositions and compounds having nucleoside phosphoramidites, and methods of making the same are provided. The compounds can also have one or more amino groups that each can be positively charged. The compounds described permit facile attachment of certain neutralizing moieties with positive charges at their terminal ends on the backbones of oligonucleotides. The compounds can be used for the treatment of cancer, autoimmune, genetic and infectious diseases.Type: ApplicationFiled: November 18, 2015Publication date: November 9, 2017Inventors: David R. Tabatadze, Ivan Yanachkov
-
Publication number: 20170320903Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.Type: ApplicationFiled: June 12, 2017Publication date: November 9, 2017Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20170320904Abstract: Precipitation promoters, which are an organic compound having one or more linear aliphatic hydrocarbon groups having not less than 10 carbon atoms, wherein the aliphatic hydrocarbon group has not less than 20 carbon atoms in total are useful for precipitating an organic compound protected by an organic group having one or more aliphatic hydrocarbon groups having not less than 10 carbon atoms from a solvent.Type: ApplicationFiled: July 20, 2017Publication date: November 9, 2017Applicant: AJINOMOTO CO., INC.Inventors: Kunihiro HIRAI, Satoshi KATAYAMA, Naoko HIROSE, Ken YAMASHITA, Taisuke ICHIMARU, Daisuke TAKAHASHI
-
Publication number: 20170320905Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-?-hydroxysteroids from ?-9,11-ene, 11-keto or 11-hydroxy-?-steroids. This invention is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.Type: ApplicationFiled: May 23, 2017Publication date: November 9, 2017Applicant: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Achampeta Rathan Prasad, John Gregory Reid, Roy A. Swaringen, Jr.
-
Publication number: 20170320906Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C.diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C.diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C.diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C.diff associated diseases and toxic megacolon.Type: ApplicationFiled: November 26, 2015Publication date: November 9, 2017Inventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
-
Publication number: 20170320907Abstract: The invention relates to compounds of formula (I): wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.Type: ApplicationFiled: November 19, 2015Publication date: November 9, 2017Inventors: Alexander WEYMOUTH-WILSON, Zofia KOMSTA, James BOYDELL, Laura WALLIS, Nathan BARTLETT, Montserrat SHELBOURNE
-
Publication number: 20170320908Abstract: The present invention relates to cyclic amino acid molecules and methods of preparing the same, and in particular the macrocyclization of amino acids or linear peptides bound to a solid support.Type: ApplicationFiled: November 17, 2015Publication date: November 9, 2017Inventors: Jennifer L. Hickey, John Mancuso, Eric Marsault, Andrew L. Roughton, Adam P. Treder, Marie-Claude J. Trembley, Andrei K. Yudin, Serge Zaretsky
-
Publication number: 20170320909Abstract: The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner.Type: ApplicationFiled: July 20, 2017Publication date: November 9, 2017Inventors: Alex Xenopoulos, Michael Phillips, Wilson Moya, Jad Jaber, Mikhail Kozlov, Ajish Potty, Matthew T. Stone, William Cataldo, Christopher Gillespie
-
Publication number: 20170320910Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.Type: ApplicationFiled: December 11, 2015Publication date: November 9, 2017Inventors: Ronald KÜHNE, Hans-Günther SCHMALZ, Matthias MÜLLER, Cedric REUTER, Arne SOICKE, Robert OPITZ, Matthias BARONE, Hartmut OSCHKINAT
-
Publication number: 20170320911Abstract: A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and formed to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, biomechanical, micro fluid, electronic, bio electronic, bio-optical, and biochemical devices. Experiments were canied out to assess functionalization and reusability of a suspended mass resonator's cantilever.Type: ApplicationFiled: January 23, 2017Publication date: November 9, 2017Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Erik Mark Krauland, Stephen Kottmann, Roberto Juan Barbero, Angela Belcher
-
Publication number: 20170320912Abstract: The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: ApplicationFiled: November 25, 2015Publication date: November 9, 2017Inventors: Per-Ola Freskgard, Eric A. Kitas
-
Publication number: 20170320913Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.Type: ApplicationFiled: June 30, 2017Publication date: November 9, 2017Inventors: Toni WEINSCHENK, Steffen WALTER, Jens FRITSCHE, Colette SONG, Harpreet SINGH
-
Publication number: 20170320914Abstract: Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.Type: ApplicationFiled: November 23, 2015Publication date: November 9, 2017Inventors: Nicolai Vladimirovich BOVIN, Stephen Micheal HENRY, Elena KORCHAGINA, Igor Leonidovich RODIONOV, Alexander Borisovich TUZIKOV
-
Publication number: 20170320915Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: ApplicationFiled: April 28, 2017Publication date: November 9, 2017Applicant: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus VAN DER BURG, Tom H. M. OTTENHOFF, Annemieke GELUK, Maria Johanna Philomena SCHOENMAEKERS-WELTERS, Annemieke M. DE JONG, Rienk OFFRINGA, Cornelis Johannes Maria MELIEF, Reinaldus Everardus Maria TOES
-
Publication number: 20170320916Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: ApplicationFiled: May 16, 2017Publication date: November 9, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea CARFI, Yingxia Wen
-
Publication number: 20170320917Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are herein described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are herein provided.Type: ApplicationFiled: June 21, 2017Publication date: November 9, 2017Inventor: Christophe Bonny
-
Publication number: 20170320918Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.Type: ApplicationFiled: July 20, 2017Publication date: November 9, 2017Applicant: AiCuris GmbH & Co. KGInventors: Olaf WEBER, Sonja Maria TENNAGELS, Angela SIEGLING, Tobias SCHLAPP, Andrew Allan MERCER, Stephen Bruce FLEMING, Hans-Dieter VOLK
-
Publication number: 20170320919Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.Type: ApplicationFiled: December 11, 2015Publication date: November 9, 2017Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
-
Publication number: 20170320920Abstract: Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates.Type: ApplicationFiled: July 25, 2017Publication date: November 9, 2017Inventors: Joseph Krebs, Paul Morrison, Jun Wang
-
Publication number: 20170320921Abstract: The invention relates to a group of isolated polypeptides and derivatives that can bind genetically to immunoglobulins or antibodies. The invention also relates to industrial and other applications of these molecules, e.g., antibody purifications.Type: ApplicationFiled: February 2, 2015Publication date: November 9, 2017Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
-
Publication number: 20170320922Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.Type: ApplicationFiled: May 18, 2017Publication date: November 9, 2017Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Mats ANDER, Goran BAUREN, Tomas BJORKMAN, Gustav RODRIGO
-
Publication number: 20170320923Abstract: The present invention relates to a proton-transport vesicle and a method for preparing the same, the proton-transfer vesicle comprising: (a) a single phospholipid bilayer liposome; (b) a rhodopsin protein; and (c) a photosystem II protein, wherein the rhodopsin protein and the photosystem II protein are inserted and located in a bilayer of the liposome. Since the heterologous photosensitive proteins are inserted and located in the bilayer of the liposome, the vesicle has an absorption wavelength band of the whole region of visible light by utilizing absorption bands of different lights of the respective photosensitive proteins. Thus, the restricted efficiency caused by utilizing only a specific wavelength in existing organisms or artificial vesicles was improved, and the wavelength region can be enlarged to the all wavelength ranges of visible light.Type: ApplicationFiled: October 10, 2014Publication date: November 9, 2017Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION SOGANG UNIVERSITYInventors: Kwan Woo SHIN, Hee Yeon KIM, Kwang-Hwan JUNG, Keel Yong LEE, Tae Kyu AHN
-
Publication number: 20170320924Abstract: According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.Type: ApplicationFiled: May 9, 2017Publication date: November 9, 2017Applicant: UNIVERSITY OF YAMANASHIInventors: Tomoyuki SASAKI, Toshiaki SHIRAI, Katsue INOUE
-
Publication number: 20170320925Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.Type: ApplicationFiled: March 15, 2017Publication date: November 9, 2017Inventors: Jasbir Seehra, Jennifer Lachey
-
Publication number: 20170320926Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.Type: ApplicationFiled: March 9, 2017Publication date: November 9, 2017Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE